Results

Results that hold at commercial scale

Ark is in use from development labs to commercial plants, with some of the largest biopharma companies in the world.

From live programs

Six results, development lab to commercial plant

43% above the program’s best-ever titer, first run

Real-time optimization surfaced feed strategy adjustments mid-run as the process crossed into uncharted territory. The result: a new record.

Case Study

40% fewer experiments in process development

A development program used model-based DoE to reduce experimentation by 40%. Each run was designed to maximize learning or provide experimental validation for regulators.

110% higher yield than statistical DoE

Model-based DoE plus in silico optimization more than doubled yield, and matched the statistical best in one-third fewer experiments.

Best titer ever for a blockbuster drug

Post-licence optimization with ambr250 scale-down modeling let the team test new strategies safely at bench scale.

Digital twin on a high-variability commercial process

A commercial process with high run-to-run variability runs Ark’s digital twin to reduce manufacturing variability.

Scale-up predicted before the first commercial batch

A development team used Ambr 250 data to quantify process performance at 15,000 L and determine the control strategy needed to match it. Tech transfer first-time-right.

“Really impressive work Ark has been doing with the team.”

Executive Director, Global Technical Operations, global biopharma

“Best run ever. Celebrating Ark!”

Senior Scientist, MSAT

Get numbers like these on your process